Elevation Oncology, Inc. (ELEV) Total Debt to Capital

Elevation Oncology develops targeted antibody-drug conjugates (ADC), scaling its business by licensing patents to industry behemoths without incurring capital expenditures. The strategy relies on the precise diagnosis of rare mutations, which increases the probability of therapeutic success. This chart of current market quotes demonstrates a total debt-to-equity ratio of 0.63. The company is currently focused on validating the efficacy of its developments through clinical trials.

The total debt-to-equity ratio measures the proportion of borrowed liabilities within the equity structure, determining the degree of financial leverage and balance sheet stability. By analyzing changes in the leverage ratio, an investor in Elevation Oncology (ELEV) can assess the biotech's ability to fund costly R&D without critical bankruptcy risk amid a high cash burn rate and dependence on external funding.